Papulosquamous Disorders and Pregnancy

Amal O. AlBalbeesi 1, Tala A. Qadoumi 1

1. Dermatology, King Saud University, Riyadh, SAU

Corresponding author: Tala A. Qadoumi, tala.qadoumi@yahoo.com

Abstract

Pregnancy can influence the course of a number of dermatologic disorders. Interestingly, these disorders can also influence pregnancy outcomes negatively, due to a variety of underlying pathogenic mechanisms. These outcomes may range from low fetal birth weight, preterm birth, and miscarriages to perineal lacerations complicating deliveries. Our review highlights the impact that papulosquamous disorders may have on pregnancy and their course throughout pregnancy. We chose papulosquamous disorders due to their relatively high prevalence worldwide compared to other dermatologic disorders. This review also sheds light on any gaps in the literature relevant to this topic that should be addressed.

Introduction And Background

Pregnancy is a time of immunologic, metabolic and hormonal changes, which can influence the course of a number of dermatologic conditions, many of which have an underlying immunologic nature. Skin manifestations during pregnancy can include physiologic changes such as hyperpigmentation, vascular skin lesions, and striae distansea. Other cutaneous manifestations range from pregnancy-specific dermatoses such as polymorphic eruption of pregnancy, atopic eczema of pregnancy, and pemphigoid gestationis to primary dermatoses unrelated to pregnancy including psoriasis and pityriasis rosea. Our review focuses on these primary dermatoses, specifically papulosquamous diseases. Pregnancy can influence the prognosis of these conditions, with some worsening throughout pregnancy or the post-partum period, others improving or stabilizing. Furthermore, certain dermatoses were found to possibly impact pregnancy outcomes resulting in stillbirths, low birth weight, or prematurity amongst other complications, emphasizing the need for closer follow-ups and prompt management.

Review

Methodology

The studies were located on PubMed using the keywords "pregnancy", "gestation", "pregnancy outcome", and/or "named papulosquamous disorders". Disorders named in the search included psoriasis, pustular psoriasis, pityriasis lichenoides, pityriasis rosea, pityriasis rubra pilaris, parapsoriasis, lichen planus, and lichen sclerosus et atrophicus. Relevant studies published from January 1, 2000 to December 31, 2021 were included in this review. Titles and abstracts were obtained and reviewed and studies that mentioned the impact of the specific disorder on pregnancy outcome and its course throughout pregnancy were included. Any other studies, including studies published outside the above-mentioned time frame, were excluded from this review. Studies regarding management of these disorders during pregnancy were also excluded. Duplicate results were excluded. Reference lists of the included studies were also extensively searched for any other relevant studies. The search resulted in 450 articles in total, 38 of which were included in this review.

Psoriasis

Psoriasis is a chronic inflammatory disorder that affects 2% of the world’s population. Psoriasis is multifactorial and immune mediated, where CD4+ T cells, either Th1 cells or Th17 cells, play an important role. Around half of patients with psoriasis are women. Three-quarters of these patients are diagnosed at the age of 40 or younger, making psoriasis prevalent during reproductive years. The course of psoriasis can be difficult to predict throughout pregnancy. Around 50% of women with psoriasis experience clinical remission during pregnancy, others (18% to 21%) show no change while some (23% to 26%) can show worsening. Moreover, 65% of patients experience worsening during the post-partum period. The Th2-mediated immune response is heightened during pregnancy which downregulates the Th1-mediated immune response responsible for psoriasis. This explains why the majority of pregnant women with psoriasis improve during pregnancy.

Psoriasis and other inflammatory conditions such as rheumatoid arthritis, systemic lupus erythematosus, and inflammatory bowel disease are known to be associated with adverse pregnancy outcomes, such as low birth weight, preterm birth, and abortions. Lima et al. found in their retrospective cohort that psoriasis...
was associated with a 1.89 fold increased risk of a poor outcome composite which they defined as a low birth weight (less than 2,500 g) and preterm birth (less than 37 weeks) [12]. Another retrospective cohort carried out by Cohen-Barak and colleagues included 68 deliveries to 35 women with moderate to severe plaque psoriasis and compared them to 257 deliveries in 256 matched women with no psoriasis. Pregnancies of women with psoriasis were found to be associated with spontaneous and induced abortions, pregnancy-induced hypertensive diseases, premature rupture of membranes, large-for-gestational-age newborns, and macrosomia [13]. A population-based cohort study done in Denmark and Sweden included 8,997 births in 6,103 women with psoriasis. In this study, psoriasis was associated with an increased risk of gestational diabetes, gestational hypertension, pre-eclampsia, elective and emergency caesarean delivery. Severe psoriasis was associated with an increased risk of low birth weight and preterm birth, as well as an increased risk for other poor outcomes mentioned above. Patients were classified as having severe psoriasis if they were receiving systemic treatments and have dispensed at least once, one of the following systemic agents: methotrexate, cyclosporine, systemic anti-psoriatic treatments and/or biologic agents such as tumor necrosis factor inhibitors, ustekinumab, leflunomide, efalizumab, abatacept before or during pregnancy [14]. Ben-David et al. evaluated 145 deliveries in women with psoriasis in a case-control study compared to 860 deliveries in non-psoriatic women. Psoriasis was found to be an independent risk factor for caesarean delivery. Psoriasis was also found to be significantly associated with chronic hypertension and recurrent abortions [15].

Another entity of psoriasis is pustular psoriasis. Pustular psoriasis of pregnancy (PPP), also known as impetigo herpetiformis, has been classically viewed as a specific dermatoses of pregnancy [16]. Recent data suggests that it may be a variant of generalized pustular psoriasis with significant fetal and maternal morbidity [16], making it worth mentioning in this review. There is however an ongoing debate on whether PPP is a pregnancy-specific dermatoses or a subtype of psoriasis. A number of causes have been postulated as part of the underlying etiology of PPP, including mutations in interleukin 36 receptor antagonist (IL36RN), which encodes the IL36 receptor antagonist [17]. Another possible cause is hypocalcemia [17], which may be triggered by pregnancy, owing to increased nutritional demands. PPP typically appears during the third trimester of pregnancy as grouped pustules over erythematous patches and plaques, that begin in intertriginous areas and progress centrifugally to involve the face, palms and soles [18]. Lesions are associated with systemic symptoms such as fever, diarrhea, tetany and delirium [18]. The lesions may then progress to erythroderma, resulting in fluid and electrolyte imbalances, secondary infections, sepsis and maternal morbidity [19]. PPP usually resolves rapidly during the post-partum period, however there is a case report documenting a post-partum flare [20].

PPP also has a significant effect on the fetus, with a risk of placental insufficiency, premature rupture of membranes, preterm labor, intrauterine growth restriction and stillbirth, prompting close monitoring, early recognition and intervention [17,21]. Fetal prognosis is often worse than maternal prognosis, with a higher risk for still-born as compared to maternal death [21]. A case reported by Kondo et al. highlighted the difference in pregnancy outcomes in two successive pregnancies. The first pregnancy resulted in stillbirth while the second resulted in a healthy baby, due to the institution of early systemic treatment (systemic steroids and antibiotics) and recommendation of delivery resolution [21]. Two separate case reports from China detailed two different PPP cases that were both managed with termination of pregnancy, due to lack of response to conventional systemic therapies, such as systemic steroids and antibiotics [22,23]. Typically, PPP will recur in subsequent pregnancies, with an earlier onset and a more severe presentation [17,24].

**Pityriasis rosea**

Pityriasis rosea (PR) is a common self-limited papulosquamous disorder that is typically associated with human herpes virus (HHV) 6/7 reactivation. It usually presents in individuals during the second or third decade of life as a single erythematous patch initially followed by an eruption of smaller similar patches. Lesions are intertriginous areas and progress centrifugally to involve the face, palms and soles. The lesions may then progress to erythroderma, resulting in fluid and electrolyte imbalances, secondary infections, sepsis and maternal morbidity [19]. PPP usually resolves rapidly during the post-partum period, however there is a case report documenting a post-partum flare [20].

PPP also has a significant effect on the fetus, with a risk of placental insufficiency, premature rupture of membranes, preterm labor, intrauterine growth restriction and stillbirth, prompting close monitoring, early recognition and intervention [17,21]. Fetal prognosis is often worse than maternal prognosis, with a higher risk for still-born as compared to maternal death [21]. A case reported by Kondo et al. highlighted the difference in pregnancy outcomes in two successive pregnancies. The first pregnancy resulted in stillbirth while the second resulted in a healthy baby, due to the institution of early systemic treatment (systemic steroids and antibiotics) and recommendation of delivery resolution [21]. Two separate case reports from China detailed two different PPP cases that were both managed with termination of pregnancy, due to lack of response to conventional systemic therapies, such as systemic steroids and antibiotics [22,23]. Typically, PPP will recur in subsequent pregnancies, with an earlier onset and a more severe presentation [17,24].

**Pityriasis rosea**

Pityriasis rosea (PR) is a common self-limited papulosquamous disorder that is typically associated with human herpes virus (HHV) 6/7 reactivation. It usually presents in individuals during the second or third decade of life as a single erythematous patch initially followed by an eruption of smaller similar patches. Lesions are intertriginous areas and progress centrifugally to involve the face, palms and soles. The lesions may then progress to erythroderma, resulting in fluid and electrolyte imbalances, secondary infections, sepsis and maternal morbidity [19]. PPP usually resolves rapidly during the post-partum period, however there is a case report documenting a post-partum flare [20].

PPP also has a significant effect on the fetus, with a risk of placental insufficiency, premature rupture of membranes, preterm labor, intrauterine growth restriction and stillbirth, prompting close monitoring, early recognition and intervention [17,21]. Fetal prognosis is often worse than maternal prognosis, with a higher risk for still-born as compared to maternal death [21]. A case reported by Kondo et al. highlighted the difference in pregnancy outcomes in two successive pregnancies. The first pregnancy resulted in stillbirth while the second resulted in a healthy baby, due to the institution of early systemic treatment (systemic steroids and antibiotics) and recommendation of delivery resolution [21]. Two separate case reports from China detailed two different PPP cases that were both managed with termination of pregnancy, due to lack of response to conventional systemic therapies, such as systemic steroids and antibiotics [22,23]. Typically, PPP will recur in subsequent pregnancies, with an earlier onset and a more severe presentation [17,24].
who did not have complications, however this finding was not found to be significant [29].

**Pityriasis lichenoides et varioliformis acuta (PLEVA) and other papulosquamous disorders**

Pityriasis lichenoides can present as a wide spectrum of manifestations with multiple variants, involving both the skin and mucous membranes. One of its variants is pityriasis lichenoides et varioliformis acuta, or PLEVA, which presents as an acute to subacute eruption of erythematous cutaneous papules that can evolve into polymorphic lesions, with varioliform scarring upon resolution [30]. Pityriasis lichenoides is more commonly seen in children and young adults [31]. A few case reports have been published in literature of PLEVA occurring in pregnant women. Lesions affecting the mucous membranes of the vagina and cervix have been implicated with premature labor and/or rupture of membranes [32,35].

There are not many studies evaluating the impact of parapsoriasis on pregnancy [34]. One study evaluated the impact that mycosis fungoids and parapsoriasis en plaque may have had on pregnancy in 12 pregnant women, nine of whom had mycosis fungoides while three had parapsoriasis. They found no adverse effect of these conditions on pregnancy outcome and no effect of pregnancy on these disorders [34]. Similarly, there are no papers, to our knowledge, studying the impact that pityriasis lichenoides chronica or pityriasis rubra pilaris may have on pregnancy.

**Lichen sclerosus et atrophicus and other lichenoid disorders**

Lichen sclerosus (LS) is a chronic inflammatory disease, mainly affecting the anogenital region. The prevalence of LS increases with age, but it may affect any age group, with a predominance in women as compared to men [35]. Lichen sclerosus has significant long-term consequences including alteration of vulvar architecture, possibly impacting the mode of delivery. LS is also associated with an increased risk of vulvar carcinoma. However, there is little literature looking into the effect that LS may have on pregnancy and its course throughout pregnancy.

A recent study carried out in 2019 by Trokoudes and Lewis assessed 36 pregnancies in 22 patients with lichen sclerosus. All patients were managed with clobetasol propionate ointment and none experienced any worsening during pregnancy, except for one patient who had a flare post partum. Thirty-three deliveries were carried out vaginally, while three deliveries were done via a caesarean section, due to failure to progress. There were 15 cases of obstetric tears, one of which was a third-degree tear in a patient whose LS was not treated during pregnancy. That same patient experienced no complications during her second pregnancy when her LS was appropriately managed and was inactive at the time of her pregnancy [36]. Another retrospective review included 33 patients diagnosed with vulvar lichen sclerosus. Eight of these patients became pregnant after their diagnosis. Of the eight deliveries, three had vaginal deliveries, two of which developed second-degree lacerations. Four of the deliveries were caesarean deliveries. It is unclear whether vulvar lichen sclerosus aggravated the risk of obstetric tears. Furthermore, 65% of the patients were symptomatic during pregnancy, whilst 25% had exacerbations. Three of these patients were noncompliant to the medications and two were not advised to apply any treatments, due to concerns of side effects of these medications during pregnancy [37].

Similarly, Nguyen et al. found in their retrospective review of 33 deliveries to 29 women with biopsy-confirmed lichen sclerosus, that the majority (82%) delivered vaginally, two delivered instrumentally and four had caesarean sections. Only one of the caesarean sections was due to extensive scarring in the vulvar region as a result of non-compliance to medication [38].

To our knowledge, there are no studies assessing the course of lichen planus during pregnancy or its impact on pregnancy outcome. This provides fertile ground for further studies into this topic as well as other dermatoses during pregnancy.

**Conclusions**

Knowledge regarding how different dermatologic disorders affect pregnancy is essential as it calls for a closer observation of the fetus and pregnancy, as a whole. It also allows for the prediction of and preparation for any issues that may arise throughout pregnancy and at the time of delivery. This, in turn, facilitates more effective management. On the other hand, knowledge of the course that these disorders normally take during pregnancies, allows physicians to remain on the lookout for possible complications and promptly make the appropriate adjustments in their treatment plan to address any possible flares or remissions. Despite the aforementioned reasons, literature in this topic is still lacking. For instance, compared to the prevalence of psoriasis worldwide especially in women of child-bearing age, studies evaluating the effect psoriasis has on pregnancy outcome are scarce. These studies also highlight the importance of disease control prior to conception and throughout pregnancy. This review allowed us to identify the gaps in literature, which provides ample opportunities for essential future research.

**Additional Information**
Disclosures

Conflicts of interest: In compliance with the ICMJE uniform disclosure form, all authors declare the following: Payment/services info: All authors have declared that no financial support was received from any organization for the submitted work. Financial relationships: All authors have declared that they have no financial relationships at present or within the previous three years with any organizations that might have an interest in the submitted work. Other relationships: All authors have declared that there are no other relationships or activities that could appear to have influenced the submitted work.

References

1. Barankin B, Silver SG, Carnuthers A: The skin in pregnancy. J Cutan Med Surg. 2002, 6:256-40. 10.1177/120547540206060308
2. Soutoo B, Aractangi S: [Skin and pregnancy]. Rev Prat. 2017, 67:411-4.
3. Soutoo B, Aractangi S: [Pregnancy-specific dermatoses]. Rev Med Interne. 2015, 36:198-202. 10.1016/j.revmed.2014.07.011
4. Nasca MR, Giafridda G, Micali G: The influence of pregnancy on the clinical evolution and prognosis of pre-existing inflammatory and autoimmune skin disorders and their management. Dermatology. 2021, 237:771-85. 10.1159/000597926
5. De Simone C, Caldaronal G, Morettal G, Piscitellal R, Riccerif F, Prignano F: Moderate-to-severe psoriasis and pregnancy: impact on fertility, pregnancy outcome and treatment perspectives. G Ital Dermatol Venereo. 2019, 154:503-14. 10.23736/S0392-0498.18.06255-7
6. Ghoreschi K, Weigert C, Röcken M: Immunopathogenesis and role of T cells in psoriasis . Clin Dermatol. 2007, 25:374-80. 10.1016/j.clindermatol.2007.08.012
7. Lomholl AB, Guenther L, Kalla S, et al.: Pregnancy outcomes in women with moderate-to-severe psoriasis from the psoriasis longitudinal assessment and registry (PSOLAR). JAMA Dermatol. 2021, 157:301-6. 10.1001/jamadermatol.2020.5595
8. Bobotis R, Gulliver WP, Monaghan K, Lynde C, Fleming P: Psoriasis and adverse pregnancy outcomes: a systematic review of observational studies. Br J Dermatol. 2016, 175:464-72. 10.1111/bjd.14547
9. Mervic L: Management of moderate to severe plaque psoriasis in pregnancy and lactation in the era of biologics. Acta Dermatovenerol Alp Pannonica Adriat. 2014, 23:27-31. 10.1557/aota.2014.4
10. Raychaudhuri SP, Navare T, Gross J, Raychaudhuri SK: Clinical course of psoriasis during pregnancy. Int J Dermatol. 2003, 42:518-20. 10.1046/j.1365-4362.2003.01760.x
11. Landau J, Moody MN, Kazakevich N, Goldberg LH: Psoriasis and the pregnant woman: what are the key considerations?. Skin Therapy Lett. 2011, 16:1-5.
12. Lima XT, Janakiraman V, Hughes MD, Kimball AB: The impact of psoriasis on pregnancy outcomes . J Invest Dermatol. 2012, 132:85-91. 10.1038/jid.2011.271
13. Cohen-Barak E, Nachum Z, Rozenman D, Ziv M: Pregnancy outcomes in women with moderate-to-severe psoriasis. J Eur Acad Dermatol Venereol. 2011, 25:1041-7. 10.1111/j.1468-3083.2010.03917.x
14. Bröms G, Haerskjold Å, Pedersen L, Berglund IA: Effect of maternal psoriasis on pregnancy and birth outcomes: a population-based cohort study from Denmark and Sweden. Acta Derm Venereol. 2018, 98:728-34. 10.2340/00015553-2925
15. Ben-David G, Shieh E, Hallak M, Levy A: Pregnancy outcome in women with psoriasis. J Reprod Med. 2008, 53:185-7.
16. Trivedi MK, Vaughn AR, Murase JE: Pustular psoriasis of pregnancy: current perspectives . Int J Womens Health. 2018, 10:109-15. 10.2147/IJWH.S125784
17. Namazi N, Dadkhahfar S: Impetigo herpetiformis: review of pathogenesis, complication, and treatment . Dermatol Res Pract. 2018, 2018:5801280. 10.1155/2018/5801280
18. Sugiuza K, Nakasuka A, Kono H, Kono M, Akiyama M: Impetigo herpetiformis with IL36RN mutations in a Chinese patient: a found haplotype of c.115+6T>C in East Asia. J Dermatol Sci. 2015, 79:319-20. 10.1111/leds.12330
19. Flynn A, Burke N, Byrne B, Gleeson N, Wynne B, Barnes L: Two case reports of generalized pustular psoriasis of pregnancy: different outcomes. Obstet Med. 2016, 9:55-9. 10.1177/1753495X15626623
20. Oumerish OY, Parish JL: Impetigo herpetiformis. Clin Dermatol. 2006, 24:101-4. 10.1016/j.clindermatol.2005.10.009
21. Kondo RN, Araujo FM, Pereira AM, Lopes VC, Martins LM: Pustular psoriasis of pregnancy (impetigo herpetiformis)--case report. An Bras Dermatol. 2013, 88:186-9. 10.1590/abd1806-4841.20132134
22. Yao X, Zhang X, Peng M, Wang H, Meng Y, Chen Y: A case of impetigo herpetiformis in which termination of pregnancy was required. J Int Med Res. 2020, 48:10.1177/0300060520093881
23. Gao QQ, Xu MR, Yao Q: Impetigo herpetiformis during pregnancy: a case report and literature review . Dermatology. 2013, 226:35-40. 10.1111/bjd.14547
24. Wamalwa EW: Recurrent impetigo herpetiformis: case report . Pan Afr Med J. 2017, 27:219. 10.11604/pamj.2017.27.219.212826
25. Monastirli A, Pasmatzi E, Badavanis G, Tsirianos D: Gestational pityriasis rosea: suggestions for approaching affected pregnant women. Acta Dermato-Venereol Crot. 2014, 24:512-5.
26. Dragó F, Broccolo F, Zaccaria E, Malnati M, Cocuzza C, Lusso P, Rebora A: Pregnancy outcome in patients with pityriasis rosea. J Am Acad Dermatol. 2008, 58:578-83. 10.1016/j.jaad.2007.05.050
27. Dragó F, Ciccarese G, Herxum A, Rebora A, Parodi A: Pityriasis rosea during pregnancy: major and minor alarming signs. Dermatology. 2018, 234:31-6. 10.1159/000498787
28. Loh TY, Cohen PR: Pityriasis rosea in pregnancy: report of a spousal occurrence and craniolymphostasis in the healthy newborn. Dermatol Pract Concept. 2016, 6:39-46. 10.5826/derp.0603a08
29. Stashower J, Bruch K, Mosby A, et al.: Pregnancy complications associated with pityriasis rosea: a multicenter retrospective study. J Am Acad Dermatol. 2021, 10.1016/j.jaad.2020.12.063
30. Khachemoune A, Blyumin ML: Pityriasis lichenoides: pathophysiology, classification, and treatment . Am J
31. Zegpi MS, Ruiz FM, Porras NK: [Pityriasis lichenoides: case report and review of the literature]. Rev Chil Pediatr. 2015, 86:121-5. 10.1016/j.rchipe.2015.04.024
32. Brazzini B, Ghersetich I, Urso C, Cianferoni L, Lotti T: Pityriasis lichenoides et varioliformis acuta during pregnancy. J Eur Acad Dermatol Venereol. 2001, 15:458-60. 10.1046/j.1468-3083.2001.00341.x
33. Eskandar MA: Pityriasis lichenoides et varioliformis acuta in pregnancy. Saudi Med J. 2001, 22:1127-9.
34. Amitay-Layish I, David M, Kafri B, Barzilai A, Feinmesser M, Hodak E: Early-stage mycosis fungoides, parapsoriasis en plaque, and pregnancy. Int J Dermatol. 2007, 46:160-5. 10.1111/j.1365-4632.2006.02963.x
35. Kirtschig G: Lichen sclerosus: presentation, diagnosis and management. Dtsch Arztebl Int. 2016, 113:337-43. 10.3238/arztebl.2016.0337
36. Trokoudes D, Lewis FM: Lichen sclerosus - the course during pregnancy and effect on delivery. J Eur Acad Dermatol Venereol. 2019, 33:e466-8. 10.1111/jdv.15788
37. Kolitz E, Gammon L, Mauskar M: Vulvar lichen sclerosus in women of reproductive age. Proc (Bayl Univ Med Cent). 2021, 34:549-51. 10.1080/08998280.2021.1885093
38. Nguyen Y, Bradford J, Fischer G: Lichen sclerosus in pregnancy: a review of 53 cases. Aust N Z J Obstet Gynaecol. 2018, 58:686-9. 10.1111/ajo.12812